Numerate Completes Integration of Pharmix Drug EngineeringTM Process

Drug Pipeline Also Acquired

SAN BRUNO, Calif.--(BUSINESS WIRE)--Numerate, Inc., a biotechnology company with a proprietary drug design capability, announced today that it has completed the integration of Pharmix Corporation’s technology platform with technologies developed at Numerate. Founded in March 2007 to rapidly deliver small molecule drug candidates with reduced risk and optimized characteristics, Numerate recently acquired all of the intellectual property of Pharmix, including all rights to Pharmix’s Drug Engineering^TM process and technology, as well as to four therapeutic programs. The terms of the transaction were not disclosed.

“These programs have lead compounds that not only validate the power of the acquired drug engineering platform, but have the potential to provide new medications for serious diseases”

“The acquisition of this pioneering drug engineering platform gives Numerate exclusive access to the first computationally-based process in which compounds designed by a computer are routinely shown to be effective in animal models,” said Nigel Duffy, Ph.D., chief technology officer of Numerate. “It is a testament both to the quality of the Pharmix codebase and the skills of the Numerate team that we have integrated the two technologies in such a short time. The new, integrated technology platform is being used today to solve drug design problems for our partners and our internal programs."

The therapeutic programs acquired from Pharmix include compounds for treating type II diabetes and cardiovascular disease (HMG-CoA reductase and p38α MAP kinase inhibitors), cancer and Celiac sprue (transglutaminase 2 inhibitors), HIV/AIDs (non-nucleoside reverse transcriptase inhibitors), and topical inflammation.

"These programs have lead compounds that not only validate the power of the acquired drug engineering platform, but have the potential to provide new medications for serious diseases,” said John Griffin, Ph.D., chief scientific officer of Numerate. "For example, our diabetes drug program provides a tremendous opportunity to reduce the risk of cardiovascular disease, particularly in patients with Type II diabetes. We have multiple patented series of compounds that have been shown to reduce cholesterol and triglyceride levels, key risk factors, in animal models of human disease.”

The Pharmix drug engineering technology platform and drug pipeline were developed and validated over a six-year period with a significant investment. The breakthrough, comprehensive drug engineering process combines advances in computer science, statistics, and molecular modeling to design compounds with predicted, optimized and validated characteristics.

“Pharmix solved many of the most difficult problems involved in the computational design of small molecule drug candidates, and Numerate now owns those solutions,” said Guido Lanza, president and chief executive officer of Numerate. “We are incredibly excited by this acquisition and will begin immediately to leverage this technology to rapidly and cost effectively pursue therapeutic programs, both internally and in the context of our ongoing and future partnerships."

About Numerate:

Numerate is a privately held biotechnology company that has developed and extensively validated a drug engineering platform that rapidly and cost-effectively delivers small molecule therapeutics optimized for efficacy, safety, and patentability. Numerate applies this technology to design and develop small molecule drugs in collaboration with a variety of partners and in the advancement of proprietary therapeutic programs, including a multi-targeted therapy for type II diabetes and cardiovascular disease. For more information, please visit our website at www.numerate.com.